Evidence map›Paper›PMID 41267972›Full record

ReviewOncology letters2026

Biology of PEST-containing nuclear proteins as potential targets in ovarian cancer (Review).

Hao Liu, Zhi-Liang Jiang, Yi Liu, Yong-Hao Zhu, Muhammad Usman Akbar, Saadullah Khattak, Zhendong Lu, Muhammad Babar Khawar, Yue Zhang, Umair Ali Khan Saddozai and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hao LiuDepartment of Medicine, Queen Mary School, Nan Chang University, Nanchang, Jiangxi 330031, P.R. China.
Zhi-Liang JiangDepartment of Clinical Medicine, School of Medicine, Henan University, Kaifeng, Henan 475004, P.R. China.
Yi LiuDepartment of Medicine, School of Stomatology, Henan University, Kaifeng, Henan 475004, P.R. China.
Yong-Hao ZhuDepartment of Medicine, School of Stomatology, Henan University, Kaifeng, Henan 475004, P.R. China.
Muhammad Usman AkbarDepartment of Biochemistry, Gomal University, Dera Ismail Khan, Khyber Pakhtunkhwa 29111, Pakistan.
Saadullah KhattakDepartment of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, P.R. China.
Zhendong LuDepartment of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, P.R. China.
Muhammad Babar KhawarDepartment of Translational Medicine, Medical College, Yangzhou University, Yangzhou, Jiangsu 225009, P.R. China.
Yue ZhangDepartment of Obstetrics and Gynecology, 988 Hospital of PLA, Zhengzhou, Henan 450000, P.R. China.
Umair Ali Khan SaddozaiDepartment of Preventive Medicine, Institute of Biomedical Informatics, Bioinformatics Center, Henan Provincial Engineering Center for Tumor Molecular Medicine, School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, P.R. China.
Xin-Ying JiKaifeng Municipal Key Laboratory for Infection and Biosafety, Henan International Joint Laboratory of Nuclear Protein Regulation, School of Basic Medical Sciences, Henan University College of Medicine, Kaifeng, Henan 475004, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ovarian cancer (OC) is the deadliest gynecological malignancy, with a 5-year survival rate of 47%, primarily due to late diagnosis and platinum resistance. Although patients with OC often exhibit an initial clinical response to platinum-based chemotherapy, they typically develop resistance to platinum, posing a significant clinical challenge. Therefore, identifying effective biomarkers and potential therapeutic targets is critical. The PEST amino acid sequence, which comprises proline (P), glutamic acid (E), serine (S) and threonine (T), functions as a structural recognition motif for the cellular degradation machinery and modulates post-translational modifications (PTMs) of nuclear proteins (NPs), regulating their activation, localization and stability. PEST sequence-enriched NPs (PEST-NPs) act as oncogenes or tumor suppressors and influence cancer metabolism, immunity and transcription, and are thus potential therapeutic targets. The present review highlighted the multifaceted roles of PEST-NPs in types of OC, focusing on how PTMs of PEST domains mediate the activation, localization and stability of PEST-NPs. PTMs regulate the stability, activation and intracellular localization of PEST-NPs, thereby driving OC initiation, progression and chemoresistance. The present review also highlighted related hallenges and opportunities, including future research to facilitate the translation of PEST-NP-based OC diagnostics and therapies from the laboratory to the clinic. Future research insights will further support the development of diagnostic and therapeutic approaches for OC based on NPs, facilitating their translation from laboratory settings to applications.

Indexed as

nuclear proteinsovarian cancerPCNPPEST sequencetherapeutics

Identifiers

PMID41267972
PMCPMC12628359

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.